4-(氨基甲基)-1,3-噻唑-2-胺 | 197893-32-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-(氨基甲基)-1,3-噻唑-2-胺
• 英文名称: 4-(aminomethyl)thiazol-2-amine
• 英文别名: 2-Amino-4-aminomethylthiazol；4-(Aminomethyl)-1,3-thiazol-2-amine
• CAS: 197893-32-6
• 化学式: C₄H₇N₃S
• mdl: MFCD08445680
• 分子量: 129.186
• InChiKey: AXYHVVSEWSUNAI-UHFFFAOYSA-N

物化性质

• 沸点：
  307.4±17.0 °C(Predicted)
• 密度：
  1.368±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  93.2
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2934100090

反应信息

• 作为反应物：
  描述：

  二碳酸二叔丁酯 、 4-(氨基甲基)-1,3-噻唑-2-胺 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以32%的产率得到tert-butyl (2-aminothiazol-4-yl)methylcarbamate
  参考文献：
  名称：

  Structure–activity relationship studies of antiplasmodial aminomethylthiazoles

  摘要：

  Structure-activity relationship (SAR) studies around a previously reported antimalarial aminomethylthiazole pyrazole carboxamide 1 are reported. Several analogues were synthesised and profiled for in vitro antiplasmodial activity against the drug-sensitive Plasmodium falciparum malaria parasite strain, NF54. Although all the reported analogues exhibited inferior in vitro antiplasmodial activity (IC50 = 0.125-173 mu M) relative to compound 1 (IC50 = 0.0203 mu M), one analogue, compound 5a, retained submicromolar activity (IC50 = 0.125 mu M). (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.09.071
• 作为产物：
  描述：

  4-(chloromethyl)thiazol-2-amine hydrochloride 在 氨 作用下， 以 甲醇 为溶剂， 反应 72.0h， 生成 4-(氨基甲基)-1,3-噻唑-2-胺
  参考文献：
  名称：

  Structure–activity relationship studies of antiplasmodial aminomethylthiazoles

  摘要：

  Structure-activity relationship (SAR) studies around a previously reported antimalarial aminomethylthiazole pyrazole carboxamide 1 are reported. Several analogues were synthesised and profiled for in vitro antiplasmodial activity against the drug-sensitive Plasmodium falciparum malaria parasite strain, NF54. Although all the reported analogues exhibited inferior in vitro antiplasmodial activity (IC50 = 0.125-173 mu M) relative to compound 1 (IC50 = 0.0203 mu M), one analogue, compound 5a, retained submicromolar activity (IC50 = 0.125 mu M). (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.09.071

文献信息

• [EN] 4 - (5 - ISOXAZOLYL OR 5 - PYRRAZOLYL -1,2,4- OXADIAZOL - 3 - YL) -MANDELIC ACID AMIDES AS SPHINGOSIN- 1 - PHOSPHATE 1 RRECEPTOR AGONISTS<br/>[FR] AMIDES D'ACIDE 4-(5-ISOXAZOLYL OU 5-PYRAZOLYL-1,2,4-OXADIAZOL-3-YL)-MANDÉLIQUE COMME AGONISTES DU RÉCEPTEUR DE LA SPHINGOSINE-1-PHOSPHATE DE TYPE 1
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011133734A1

  公开（公告）日：2011-10-27

  Disclosed are compounds of Formula (I) or stereoisomers, salts, or prodrugs thereof, wherein: Q is, or R1 is phenyl substituted with zero to 3 substituents; and R1, R2, R3, R4, R5, and G are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  揭示了Formula (I)的化合物或其立体异构体、盐或前药，其中：Q是，或者R1是苯基，其上取代基为零至3个；而R1、R2、R3、R4、R5和G在此处有定义。还揭示了将这些化合物用作G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或紊乱方面具有用处，如自身免疫疾病和血管疾病。
• Rational Design of Highly Potent, Selective, and Bioavailable SGK1 Protein Kinase Inhibitors for the Treatment of Osteoarthritis
  作者：Nis Halland、Friedemann Schmidt、Tilo Weiss、Ziyu Li、Jörg Czech、Joachim Saas、Danping Ding-Pfennigdorff、Matthias K. Dreyer、Carsten Strübing、Marc Nazare

  DOI：10.1021/acs.jmedchem.1c01601

  日期：2022.1.27

  high requirements for the drug selectivity, pharmacokinetic, and safety profile. We describe the identification of a highly selective druglike 1H-pyrazolo[3,4-d]pyrimidine SGK1 inhibitor 17a that matches both safety and pharmacokinetic requirements for oral dosing. Rational compound design was facilitated by a novel hSGK1 co-crystal structure, and multiple ligand-based computer models were applied to guide

  丝氨酸/苏氨酸激酶 SGK1 是 β-连环蛋白途径的激活剂，是软骨降解的强大刺激剂，在患病的骨关节炎软骨中被发现在基因组控制下被上调。今天，没有口服疾病缓解治疗可用，并且该适应症中的慢性治疗对药物选择性、药代动力学和安全性提出了很高的要求。我们描述了一种高选择性药物样 1 H-吡唑并[3,4- d ]嘧啶 SGK1 抑制剂17a的鉴定符合口服给药的安全性和药代动力学要求。新的 hSGK1 共晶结构促进了合理的化合物设计，并应用了多个基于配体的计算机模型来指导化合物 ADMET 的化学优化和选择性曲线。选择化合物用于小鼠股骨头软骨外植体模型中的亚慢性机制研究，化合物17a成为药物样 SGK1 抑制剂，具有高度优化的特性，适合口服给药，作为一种新型的、潜在的骨关节炎疾病缓解剂。
• Discovery of benzamides as potent human β3 adrenergic receptor agonists
  作者：Cheng Zhu、Nam F. Kar、Bing Li、Melissa Costa、Karen H. Dingley、Jerry Di Salvo、Sookhee N. Ha、Amanda L. Hurley、Xiaofang Li、Randy R. Miller、Gino M. Salituro、Mary Struthers、Ann E. Weber、Jeffrey J. Hale、Scott D. Edmondson

  DOI：10.1016/j.bmcl.2015.11.030

  日期：2016.1

  The paper will describe the synthesis and SAR studies that led to the discovery of benzamide (reverse amide) as potent and selective human β3-adrenergic receptor agonist. Based on conformationally restricted pyrrolidine scaffold we discovered earlier, pyrrolidine benzoic acid intermediate 22 was synthesized. From library synthesis and further optimization efforts, several structurally diverse reverse

  本文将描述合成和SAR研究，从而发现苯甲酰胺（反向酰胺）作为有效的选择性人β3-肾上腺素能受体激动剂。基于我们先前发现的构象受限的吡咯烷支架，合成了吡咯烷苯甲酸中间体22。通过文库合成和进一步的优化工作，发现几种结构上不同的反向酰胺（例如24c和24i）具有出色的人β3-肾上腺素能效力以及对β1和β2受体的良好选择性。除了人β1，β2，β3和hERG数据外，还将描述所选化合物的PK。
• Design, Synthesis, and Crystal Structures of 6-Alkylidene-2′-Substituted Penicillanic Acid Sulfones as Potent Inhibitors of <i>Acinetobacter baumannii</i> OXA-24 Carbapenemase
  作者：German Bou、Elena Santillana、Anjaneyulu Sheri、Alejandro Beceiro、Jared M. Sampson、Matthew Kalp、Christopher R. Bethel、Anne M. Distler、Sarah M. Drawz、Sundar Ram Reddy Pagadala、Focco van den Akker、Robert A. Bonomo、Antonio Romero、John D. Buynak

  DOI：10.1021/ja104092z

  日期：2010.9.29

  enzymes are found in multi-drug resistant (MDR) Acinetobacter baumannii and Pseudomonas aeruginosa, novel β-lactamase inhibitors are urgently needed. Five unique 6-alkylidene-2'-substituted penicillanic acid sulfones (1-5) were synthesized and tested against OXA-24, a clinically important β-lactamase that inactivates carbapenems and is found in A. baumannii. Based upon the roles Tyr112 and Met223 play

  D 类 β-内酰胺酶代表了一类不断增长的多样化青霉素失活酶，这些酶通常对商业 β-内酰胺酶抑制剂具有抗性。由于在多重耐药（MDR）鲍曼不动杆菌和铜绿假单胞菌中发现了许多此类酶，因此迫切需要新型β-内酰胺酶抑制剂。合成了五种独特的 6-亚烷基-2'-取代的青霉烯酸砜 (1-5)，并针对 OXA-24 进行了测试，OXA-24 是一种临床上重要的 β-内酰胺酶，可灭活碳青霉烯类，并且存在于鲍曼不动杆菌中。基于 Tyr112 和 Met223 在 OXA-24 β-内酰胺酶中的作用，我们还设计了两种变体（Tyr112Ala 和 Tyr112Ala，Met223Ala）来测试由这些残基形成的疏水隧道影响抑制剂识别的假设。针对 OXA-24 和两种 OXA-24 β-内酰胺酶变体的 IC(50) 值范围为 10 ± 1（4 对 WT）至 338 ± 20 nM（5 对 Tyr112Ala、Met223Ala）。化合物
• MANDELAMIDE HETEROCYCLIC COMPOUNDS
  申请人：Cherney Robert J.

  公开号：US20130045964A1

  公开（公告）日：2013-02-21

  Disclosed are compounds of Formula (I) or stereoisomers, salts, or prodrugs thereof, wherein: Q is, or R 1 is phenyl substituted with zero to 3 substituents; and R 1 , R 2 , R 3 , R 4 , R 5 , and G are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  本发明涉及式（I）的化合物或其立体异构体、盐或前药，其中：Q是，或R1是带有零到3个取代基的苯基；R1、R2、R3、R4、R5和G在此处被定义。还公开了使用这些化合物作为选择性G蛋白偶联受体S1P1的激动剂的方法，以及包含这些化合物的制药组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或疾病的进展中有用，例如自身免疫性疾病和血管疾病。